Posted by Michael Wonder on 18 Jan 2024
Verastem Oncology granted fast track designation for combination of avutometinib and sotorasib for the treatment of KRAS G12C mutant non-small-cell lung cancer
18 January 2024 - On-going RAMP 203 trial assessing a more complete vertical blockade with RAF/MEK and KRAS G12C inhibition along RAS pathway to improve outcomes in KRAS G12C mutant non-small-cell lung cancer.
Verastem Oncology today announced the US FDA has granted fast track designation to Verastem Oncology’s investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor, Lumakras (sotorasib), for the treatment of patients with KRAS G12C mutant metastatic non-small cell lung cancer who have received at least one prior systemic therapy and have not been previously treated with a KRAS G12C inhibitor.
